Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer's disease, a progressive neurodegenerative disease characterized by cognitive and functional decline. Alzheimer's disease is the most common cause of dementia, affecting an esti.

Business Wire • Dec 8, 2025

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL). There are currently limited and inadequate treatment options for the millions of people globally living with SHTG.

Business Wire • Dec 2, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Annual Healthcare Conference – December 2-4, 2025 Type: Fireside Chat Presentation Date/Time: December 3, 2025, 10:30 a.m. EST 8th Annual Evercore Healthcare Conference – December 2-4, 2025 Type: Fireside Chat Presentation Date/Time: December 4, 2025, 10:00 a.m. EST World Congress of Insulin Resistance, Diabete.

Business Wire • Dec 1, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.

Seeking Alpha • Nov 28, 2025

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

The biotech published its latest set of annual results. It's now got several revenue streams that are already significantly boosting the fundamentals.

The Motley Fool • Nov 27, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Dina Ramadane - BofA Securities, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Madison Wynne El-Saadi - B.

Seeking Alpha • Nov 26, 2025

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results. “The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead. REDEMPLO is the first and on.

Business Wire • Nov 25, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.

Business Wire • Nov 24, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce Given Conference Call Participants Ryan Mcelroy - Leerink Partners LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Farzin Haque - Jefferies LLC, Research Division Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Avraham Novick - Morgan Stanley, Research Division Chi Meng Fong - BofA Securities, Research Division John Peyton Bohnsack - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division William Pickering - Sanford C.

Seeking Alpha • Nov 19, 2025

US FDA approves Arrowhead's genetic disorder drug

The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed on Tuesday.

Reuters • Nov 18, 2025